File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Antibody-based inhibitors of HIV infection

TitleAntibody-based inhibitors of HIV infection
Authors
KeywordsAntibody therapeutics
Envelope glycoprotein
Fusion
HIV
Neutralisation
Vaccine
Issue Date2006
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ebt
Citation
Expert Opinion On Biological Therapy, 2006, v. 6 n. 5, p. 523-531 How to Cite?
AbstractThe demand for new treatment options against HIV is becoming increasingly desperate as the side effects and the expansion and spread of drug-resistant virus within the infected population limit the clinical benefits provided by available anti-HIV drugs. Preparations of polyclonal antibodies have a long history of proven clinical utility against some viruses; however, they have enjoyed very limited success against HIV. Recent clinical trials and in vitro experiments suggest that monoclonal antibodies against HIV may have promise clinically. These antibodies and antibody-based reagents target either the viral envelope glycoprotein, the receptor (CD4) or coreceptor (CCR5) molecules, or transition-state structures that appear during viral entry. The challenge is whether an antibody-based therapy can be identified (with or without their small molecule brethren) that presents long-term clinical efficacy, lowtoxicity and minimal risk of clinical failure from viral resistance.
Persistent Identifierhttp://hdl.handle.net/10722/157444
ISSN
2021 Impact Factor: 5.589
2020 SCImago Journal Rankings: 1.088
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChoudhry, Ven_US
dc.contributor.authorZhang, MYen_US
dc.contributor.authorDimitrova, Den_US
dc.contributor.authorPrabakaran, Pen_US
dc.contributor.authorDimitrov, ASen_US
dc.contributor.authorFouts, TRen_US
dc.contributor.authorDimitrov, DSen_US
dc.date.accessioned2012-08-08T08:50:01Z-
dc.date.available2012-08-08T08:50:01Z-
dc.date.issued2006en_US
dc.identifier.citationExpert Opinion On Biological Therapy, 2006, v. 6 n. 5, p. 523-531en_US
dc.identifier.issn1471-2598en_US
dc.identifier.urihttp://hdl.handle.net/10722/157444-
dc.description.abstractThe demand for new treatment options against HIV is becoming increasingly desperate as the side effects and the expansion and spread of drug-resistant virus within the infected population limit the clinical benefits provided by available anti-HIV drugs. Preparations of polyclonal antibodies have a long history of proven clinical utility against some viruses; however, they have enjoyed very limited success against HIV. Recent clinical trials and in vitro experiments suggest that monoclonal antibodies against HIV may have promise clinically. These antibodies and antibody-based reagents target either the viral envelope glycoprotein, the receptor (CD4) or coreceptor (CCR5) molecules, or transition-state structures that appear during viral entry. The challenge is whether an antibody-based therapy can be identified (with or without their small molecule brethren) that presents long-term clinical efficacy, lowtoxicity and minimal risk of clinical failure from viral resistance.en_US
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ebten_US
dc.relation.ispartofExpert Opinion on Biological Therapyen_US
dc.subjectAntibody therapeutics-
dc.subjectEnvelope glycoprotein-
dc.subjectFusion-
dc.subjectHIV-
dc.subjectNeutralisation-
dc.subjectVaccine-
dc.subject.meshAnimalsen_US
dc.subject.meshAntigens, Cd4 - Genetics - Immunologyen_US
dc.subject.meshClinical Trials As Topicen_US
dc.subject.meshHiv Antibodies - Immunology - Therapeutic Useen_US
dc.subject.meshHiv Envelope Protein Gp120 - Immunologyen_US
dc.subject.meshHiv Envelope Protein Gp41 - Immunologyen_US
dc.subject.meshHiv Infections - Therapyen_US
dc.subject.meshHiv-1 - Immunologyen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunotherapy - Trendsen_US
dc.subject.meshReceptors, Ccr5 - Immunologyen_US
dc.titleAntibody-based inhibitors of HIV infectionen_US
dc.typeArticleen_US
dc.identifier.emailZhang, MY:zhangmy@hku.hken_US
dc.identifier.authorityZhang, MY=rp01409en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1517/14712598.6.5.523en_US
dc.identifier.pmid16610981-
dc.identifier.scopuseid_2-s2.0-33646581741en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33646581741&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume6en_US
dc.identifier.issue5en_US
dc.identifier.spage523en_US
dc.identifier.epage531en_US
dc.identifier.isiWOS:000237554700008-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridChoudhry, V=8530897500en_US
dc.identifier.scopusauthoridZhang, MY=35316639300en_US
dc.identifier.scopusauthoridDimitrova, D=13106161100en_US
dc.identifier.scopusauthoridPrabakaran, P=6603634046en_US
dc.identifier.scopusauthoridDimitrov, AS=7101600999en_US
dc.identifier.scopusauthoridFouts, TR=6603607043en_US
dc.identifier.scopusauthoridDimitrov, DS=7202564539en_US
dc.identifier.citeulike630963-
dc.identifier.issnl1471-2598-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats